Table 2.
Summary of anticipated absolute differences comparing glucagon-like peptide-1 receptor agonist treatment with placebo treatment per 1000 patients with diabetes type 2 and with very low to very high cardiovascular risk, treated for five years
| Risk* | All cause mortality | Cardiovascular mortality | Non-fatal myocardial infarction | Non-fatal stroke | Kidney failure | Hospital admission for heart failure | Severe gastrointestinal events | Body weight |
|---|---|---|---|---|---|---|---|---|
| Very low | 2 fewer (3 fewer to 1 fewer) ⊕⊕⊕ |
2 fewer (3 fewer to 1 fewer) ⊕⊕⊕ |
2 fewer (4 fewer to 0) ⊕⊕⊕ |
5 fewer (7 fewer to 2 fewer) ⊕⊕⊕ |
0 (1 fewer to 0) ⊕⊕⊕ |
0 (1 fewer to 0) ⊕⊕⊕ |
58 more (9 more to 142 more) ⊕⊕ |
145 kg lower (1.72 lower to 1.18 lower) over 6 months ⊕⊕ |
| Low cardiovascular risk factors | 8 fewer (11 fewer to 4 fewer) ⊕⊕⊕⊕ |
5 fewer (9 fewer to 2 fewer) ⊕⊕⊕⊕ |
4 fewer (8 fewer to 1 fewer) ⊕⊕⊕⊕ |
9 fewer (13 fewer to 4 fewer) ⊕⊕⊕⊕ |
2 fewer (1 fewer to 3 fewer) ⊕⊕⊕⊕ |
2 fewer (4 fewer to 1 more) ⊕⊕⊕⊕ |
||
| Moderate | 13 fewer (18 fewer to 6 fewer) ⊕⊕⊕⊕ |
9 fewer (15 fewer to 1 fewer) ⊕⊕⊕⊕ |
8 fewer (15 fewer to 1 fewer) ⊕⊕⊕⊕ |
16 fewer (24 fewer to 7 fewer) ⊕⊕⊕⊕ |
4 fewer (7 fewer to 2 fewer) ⊕⊕⊕⊕ |
4 fewer (11 fewer to 2 more) ⊕⊕⊕⊕ |
||
| High | 17 fewer (25 fewer to 9 fewer) ⊕⊕⊕⊕ |
12 fewer (20 fewer to 4 fewer) ⊕⊕⊕⊕ |
9 fewer (16 fewer to 1 fewer) ⊕⊕⊕⊕ |
17 fewer (26 fewer to 7 fewer) ⊕⊕⊕⊕ |
19 fewer (28 fewer to 7 fewer) ⊕⊕⊕⊕ |
6 fewer (14 fewer to 3 more) ⊕⊕⊕⊕ |
||
| Very high | 24 fewer (35 fewer to 12 fewer) ⊕⊕⊕⊕ |
18 fewer (30 fewer to 6 fewer) ⊕⊕⊕⊕ |
13 fewer (24 fewer to 2 fewer) ⊕⊕⊕⊕ |
25 fewer (39 fewer to 11 fewer) ⊕⊕⊕⊕ |
29 fewer (44 fewer to 10 fewer) ⊕⊕⊕⊕ |
11 fewer (28 fewer to 5 more) ⊕⊕⊕⊕ |
*
Risk categories represent the following patient populations: very low=no or less than three cardiovascular risk factors; low=three or more cardiovascular risk factors; moderate=cardiovascular disease; high=chronic kidney disease (reduced glomerular filtration rate or macroalbuminuria); very high=cardiovascular disease and chronic kidney disease.
Certainty of the evidence for each estimate is shown: high certainty ⊕⊕⊕⊕; moderate certainty ⊕⊕⊕; low certainty ⊕⊕; very low certainty ⊕.